Reuters logo
BRIEF-Ardelyx announces Tenapanor reduces pain caused by IBS-C through inhibition of TRPV-1 signaling
October 16, 2017 / 12:31 PM / in a month

BRIEF-Ardelyx announces Tenapanor reduces pain caused by IBS-C through inhibition of TRPV-1 signaling

Oct 16 (Reuters) - Ardelyx Inc

* Ardelyx announces Tenapanor reduces pain caused by IBS-c through inhibition of TRPV-1 signaling

* Ardelyx - ‍data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation​

* Ardelyx Inc - ‍moving forward to submit first nda to U.S. FDA for indication in second half of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below